Related Experiment Video
Updated: Oct 14, 2025
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers
Aleena K S Arakaki1, Frank Szulzewsky1, Mark R Gilbert2
1Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Abstract:
Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of patients. Recent technological advances have identified molecular drivers of some of these rare cancers which we can now use to generate representative preclinical models of these diseases. In this review, we outline the advantages and disadvantages of different models, emphasizing the utility of various in vitro and ex vivo models for target discovery and mechanistic inquiry and multiple in vivo models for therapeutic validation. We also highlight recent literature on preclinical model generation and screening approaches for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors, all of which are rare CNS cancers that have recently established genetic or epigenetic drivers. These preclinical models are critical to advancing targeted therapeutics for these rare CNS cancers that currently rely on conventional treatments.
Insights
Developing preclinical models for rare central nervous system (CNS) cancers is crucial. These models aid in discovering new therapeutic targets and validating treatments for CNS tumors with poor prognoses.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Rare central nervous system (CNS) tumors present significant challenges due to poor prognosis and limited treatment options.
- Historically, studying these rare cancers has been hindered by small patient cohorts.
- Recent advances in molecular profiling are identifying key drivers, enabling the development of better research models.
Purpose of the Study:
- To review the advantages and disadvantages of various preclinical models for rare CNS tumors.
- To emphasize the utility of in vitro, ex vivo, and in vivo models for different research stages.
- To highlight recent progress in generating and screening models for specific rare CNS cancers.
Main Methods:
- Review of current literature on preclinical model generation for rare CNS tumors.
- Analysis of in vitro, ex vivo, and in vivo model systems.
- Focus on models for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors.
Main Results:
- Preclinical models, including in vitro, ex vivo, and in vivo systems, are essential for understanding rare CNS cancers.
- These models facilitate target discovery, mechanistic studies, and therapeutic validation.
- Specific examples of model development for ependymomas, histone mutated high-grade gliomas, and atypical teratoid rhabdoid tumors are discussed.
Conclusions:
- The development and utilization of representative preclinical models are critical for advancing targeted therapies for rare CNS cancers.
- These models offer a path forward for diseases currently lacking effective conventional treatments.
- Continued innovation in preclinical modeling is key to improving outcomes for patients with rare CNS tumors.
More Related Videos
06:52The Establishment and Utilization of Patient Derived Xenograft Models of Central Nervous System Metastasis
Published on: May 7, 2021
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
